NASDAQ:ONXX - Onyx Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileFinancialsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST). Receive ONXX News and Ratings via Email Sign-up to receive the latest news and ratings for ONXX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A SymbolNASDAQ:ONXX CUSIP68339910 WebN/A Phone+1-650-2660000 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions What is Onyx Pharmaceuticals' stock symbol? Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX." What is the consensus analysts' recommendation for Onyx Pharmaceuticals? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onyx Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Has Onyx Pharmaceuticals been receiving favorable news coverage? News articles about ONXX stock have been trending positive on Sunday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Onyx Pharmaceuticals earned a news impact score of 0.39 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.31 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of Onyx Pharmaceuticals? Shares of ONXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Onyx Pharmaceuticals? Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000. MarketBeat Community Rating for Onyx Pharmaceuticals (NASDAQ ONXX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 285 (Vote Outperform)Underperform Votes: 208 (Vote Underperform)Total Votes: 493MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ONXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONXX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?